Anthony Ku

Hi everyone! My name is Anthony Ku and I’m from Toronto, Canada. I completed my B.Sc in radiation sciences followed by my Ph.D in pharmaceutical sciences at the University of Toronto.

As a postdoctoral fellow of the molecular imaging program at Stanford, I am developing an immunoPET strategy for immunotherapy.

Publications

1. Ku A†, Kondo M†, Cai Z†, Meens J, Li MR, Ailles L, Reilly RM. Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab’)2 in NRG mice with HNSCC patient-derived xenografts based on [64Cu]Cu-DOTA-panituumab F(ab’)2 – Implications for a PET theranostic strategy. EJNMMI Radiopharm Chem. 2021, 12;6(1):25

2. Le PJ, Miersch S, Jarvik N, Ku A, Forbes M, Sidhu S, Reilly RM, Winnik MA. Site-specific Conjugation of Metal-Chelating Polymers to Anti-Frizzled 2 Antibodies via Microbial Transglutaminase for Radiotheranostic Applications. Biomacromolecules. 2021,22 (6): 2491–2504

3. Facca VJ†, Al-Saden N†, Ku A, Reilly R.M. Pertuzumab Fab-His6-99mTc for Preclinical SPECT/CT Imaging of HER2-Overexpressing Cancer Xenografts. Mol Imaging Biol.2021, 1-10

4. Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV,Ailles L, Hedley D, Reilly RM. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with (99m)Tc(I) Tricarbonyl Complex. Mol Pharm. 2019,16 (8):3559-68.

5. Ku A†, Facca VJ†, Cai Z, Reilly RM. Auger electrons for cancer therapy – a review. EJNMMI Radiopharm Chem. 2019,4 (1):27.